CL
BHVN icon

CSS LLC’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

CSS LLC’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-194,903
Closed -$29.5M – 1321
2022
Q3 		$29.5M Buy
194,903
+190,903
+4,773% +$28.3M 1.39% 10
2022
Q2 		$583K Buy
+4,000
New +$511K 0.02% 535
2020
Q2 		– Sell
-2,781
Closed -$148K – 830
2020
Q1 		$95K Buy
+2,781
New +$127K 0.01% 499

Other funds holding BHVN

Liontrust Investment Partners
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
Birchview Capital
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Blue Trust Inc
Blue Trust Inc Alpharetta, Georgia $9.5B AUM 13.02% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
McElhenny Sheffield Capital Management
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

CSS LLC's BHVN Position: Q4 2022 in Review

CSS LLC sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 194,903 shares — an estimated $29.5M sold.

CSS LLC first reported a position in BHVN in Q1 2020 and held it in 3 quarters. The position peaked at $29.5M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • CSS LLC reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • CSS LLC sold 194,903 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $29.5M.
  • CSS LLC first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2020 and held it in 3 quarters.
  • CSS LLC's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $29.5M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on CSS LLC's 13F filing for Q4 2022, filed 14 Feb 2023.